Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Database
Language
Publication year range
1.
Molecules ; 25(18)2020 Sep 21.
Article in English | MEDLINE | ID: mdl-32967164

ABSTRACT

The inflammatory process implicates homeostasis disruption and increased production of inflammatory mediators. Myeloid differentiation primary response 88 (MyD88) is an essential protein recruited after lipopolysaccharide (LPS) and interleukin (IL)-1ß stimulation, a process that converges in nuclear factor kappa B (NF-κB) activation, as well as a transcription of several genes of both pro- and anti-inflammatory cytokines. The inhibition of MyD88 has shown efficacy by decrease inflammatory response, and has demonstrated potential application as a therapeutic target in chronic diseases. In this study, we investigate the effect of MyD88 dimerisation inhibitor ST2825 on cytokine production from rhIL-1ß and LPS-stimulated peripheral blood mononuclear cells (PBMC) from healthy blood donors (HBD). ST2825 significantly downregulates the production of IFN-γ, IL-6, IL-12, IL-2, IL-15, IL-7, VEGF, IL-1Ra, IL-4, IL-5, IL-13 and IL-9 (p < 0.05) in LPS-stimulated PBMC. Moreover, ST2825 had a relatively low impact on IL-1ß signalling pathway inhibition, showing that only a few specific cytokines, such as IFN-γ and IL-1Ra, are inhibited in rhIL-1ß-stimulated PBMC (p < 0.01). In conclusion, MyD88 dimerisation inhibitor ST2825 showed high efficacy by inhibiting pro- and anti-inflammatory cytokine production in LPS-stimulated PBMC. Moreover, although rhIL-1ß induced a sustained cytokine production (p < 0.05), ST2825 did not show a significant effect in the secretion of neither pro- nor anti-inflammatory cytokines in rhIL-1ß-stimulated PBMC.


Subject(s)
Down-Regulation/drug effects , Heterocyclic Compounds, 2-Ring/pharmacology , Interleukin-1beta/metabolism , Leukocytes, Mononuclear/drug effects , Lipopolysaccharides/pharmacology , Myeloid Differentiation Factor 88/chemistry , Protein Multimerization/drug effects , Spiro Compounds/pharmacology , Anti-Inflammatory Agents/pharmacology , Dose-Response Relationship, Drug , Humans , Inflammation/metabolism , Leukocytes, Mononuclear/metabolism , Protein Structure, Quaternary
2.
Med Chem ; 14(3): 304-310, 2018.
Article in English | MEDLINE | ID: mdl-28676004

ABSTRACT

BACKGROUND: Over the last few years, fungal infections have emerged as a worrisome global public health problem. Candidiasis is a disease caused by Candida species and has been a problem worldwide mainly for immunosuppressed patients. Lately, the resistant strains and side effects have been reported as important issues for treating Candidiasis, which have to be solved by identifying new drugs. OBJECTIVE: The goal of this work was to synthesize a series of 1,3-benzoxathiol-2-one derivatives, XYbenzo[ d][1,3]oxathiol-2-ones, and evaluate their antifungal activity against five Candida species. METHODS: In vitro antifungal screening test and minimum inhibitory concentration determination were performed according to CLSI protocols using ketoconazole as the reference drug. The cytotoxicity of the most active compounds was evaluated by hemolysis and MTT (Vero cells) assays. RESULTS: Compounds 2 (XY = 6-hydroxy-5-nitro, MIC = 4-32 µg/mL) and 7 (XY = 6-acetoxy-5-nitro, MIC =16-64 µg/mL) showed good results when compared with current antifungals in CLSI values (MIC = 0.04-250 µg/mL). These compounds exhibited a safer cytotoxicity as well as a lower hemolytic profile than ketoconazole. CONCLUSION: Overall, the in vitro results pointed to the potential of compounds 2 and 7 as new antifungal prototypes to be further explored.


Subject(s)
Antifungal Agents/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Lactones/pharmacology , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Antifungal Agents/toxicity , Candida/drug effects , Crystallography, X-Ray , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/chemistry , Heterocyclic Compounds, 2-Ring/toxicity , Lactones/chemical synthesis , Lactones/chemistry , Lactones/toxicity , Microbial Sensitivity Tests , Molecular Structure
3.
Genet Mol Res ; 15(1): 15016826, 2016 Mar 04.
Article in English | MEDLINE | ID: mdl-26985932

ABSTRACT

The purpose of this study was to investigate the effect of ST2825, an inhibitor of myeloid differentiation factor 88 (MyD88), on the proliferation and apoptosis of human hepatocellular carcinoma (HCC) cells as well as the potential mechanism and clinical significance of ST2825 in the treatment of HCC. Immunohistochemical staining with an MyD88 antibody was performed on tissues from 80 human HCC patients and adjacent normal tissues. In the in vitro experiment, human HCC HepG-2 cells cultured in vitro were divided into the following groups: blank, control (1% DMSO), low-dose (2 µM), medium-dose (10 µM), and high-dose ST2825 (20 µM). Cell apoptosis was detected by the Annexin V-FITC assay, and HepG-2 cell proliferation was detected by the MTT assay. The expression of IκB, p65, cyclin D1, caspase-3, and bcl-2 in the cells after a 48-h treatment was assayed by western blot analysis. MyD88 expression in the HCC tissue was significantly higher than that in the adjacent normal tissue (P < 0.05). The proliferation and apoptosis rates of control HCC cells displayed no significant differences compared with those of the blank group (P > 0.05). Compared with the control, ST2825 significantly inhibited the proliferation of and promoted the apoptosis of HCC cells. Moreover, ST2825 significantly decreased bcl-2 expression, increased cleaved caspase-3 expression (P < 0.05), and reduced p65 nuclear expression (P < 0.05) in a dose-dependent manner. ST2825 inhibits the proliferation of and promotes the apoptosis of HCC cells, thereby suggesting that ST2825 may be a new drug for HCC treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Hepatocellular/metabolism , Heterocyclic Compounds, 2-Ring/pharmacology , Liver Neoplasms/metabolism , Myeloid Differentiation Factor 88/metabolism , Spiro Compounds/pharmacology , Apoptosis , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Caspase 3/metabolism , Cell Proliferation/drug effects , Cyclin D1/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Hep G2 Cells , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Proto-Oncogene Proteins c-bcl-2/metabolism
4.
J Nat Prod ; 78(3): 557-61, 2015 Mar 27.
Article in English | MEDLINE | ID: mdl-25738226

ABSTRACT

Investigation of antifungal natural products from the marine sponge Pseudaxinella reticulata from the Bahamas led to the discovery of new crambescin homologues (1, 2) and enantiomers (3, 4) of known natural products. The cyclic-guanidine structures were solved through analysis of 2D NMR, MS-MS, and CD data. The absolute configurations of 1-4 were established as 13R-opposite of known homologues reported from Crambe crambe obtained from the Mediterranean Sea-by comparison of their CD spectra with predicted Cotton effects obtained from DFT calculations. Antifungal activities of 1-4 against the pathogenic strains Candida albicans and Cryptococcus sp. were observed to correlate potency (MIC50 and MIC90) with the length of the alkyl side chain.


Subject(s)
Antifungal Agents/isolation & purification , Antifungal Agents/pharmacology , Biological Products/isolation & purification , Biological Products/pharmacology , Guanidines/isolation & purification , Guanidines/pharmacology , Heterocyclic Compounds, 2-Ring/isolation & purification , Heterocyclic Compounds, 2-Ring/pharmacology , Porifera/chemistry , Animals , Antifungal Agents/chemistry , Bahamas , Biological Products/chemistry , Candida albicans/drug effects , Cryptococcus/drug effects , Guanidines/chemistry , Heterocyclic Compounds, 2-Ring/chemistry , Marine Biology , Mediterranean Sea , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , Stereoisomerism , Structure-Activity Relationship
5.
J Clin Psychopharmacol ; 35(1): 22-33, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25493397

ABSTRACT

OBJECTIVE: AZD6280 is a novel γ-aminobutyric acid A receptor modulator with higher in vitro efficacy at the α2,3 subtypes as compared to the α1 and α5 subtypes. This study compared the pharmacodynamic effects of single oral dose AZD6280 10 mg and 40 mg on the central nervous system with 2 mg of lorazepam. METHODS: Sixteen healthy males were enrolled into the double-blind, randomized, 4-way crossover study. Two validated central nervous system test batteries, Neurocart and CogState, were administered to measure drug effects on cognition, neurophysiologic function, and psychomotor and subjective feelings. Statistical analysis was performed using mixed model analysis of variance, with fixed factors of treatment, period, time and treatment by time, and random factors of subject, subject by treatment and subject by time, and the average prevalue as covariate. RESULTS: Most pharmacodynamic parameters were affected by lorazepam. AZD6280 induced dose-dependent smaller-than-lorazepam effects on saccadic peak velocity (SPV) (AZD6280, 10 mg vs. AZD6280, 40 mg vs. lorazepam [deg/s]: -22.6 vs. -50.0 vs. -62.9, P < 0.001), whereas the impacts on adaptive-tracking, body-sway, smooth-pursuit, and the one-card-learning tests were significant but much smaller than lorazepam. Thus, the slopes of regression lines for the ΔLog(Sway)-ΔSPV, ΔTracking-ΔSPV, and ΔSmooth-ΔSPV relations were flatter with AZD6280 than with lorazepam. AZD6280 caused a distinct electroencephalography signature from that of lorazepam. CONCLUSIONS: The SPV responses to AZD6280 suggest potential concentration-related anxiolytic effects, whereas the smaller SPV-normalized effects of AZD6280 on various non-SPV pharmacodynamic parameters suggest a more favorable side effect profile compared to lorazepam. Overall, the pharmacodynamic profile of AZD6280 matches the pharmacological specificity and selectivity of this compound at the α2,3 γ-aminobutyric acid A receptor subtypes.


Subject(s)
GABA Modulators/pharmacology , Healthy Volunteers , Heterocyclic Compounds, 2-Ring/pharmacology , Receptors, GABA-A , Adolescent , Adult , Cross-Over Studies , Double-Blind Method , GABA Modulators/metabolism , Heterocyclic Compounds, 2-Ring/metabolism , Humans , Male , Middle Aged , Receptors, GABA-A/metabolism , Treatment Outcome , Young Adult
6.
Molecules ; 18(5): 5482-97, 2013 May 13.
Article in English | MEDLINE | ID: mdl-23669632

ABSTRACT

New hetaryl- and alkylidenerhodanine derivatives 3a-d, 3e, and 4a-d were prepared from heterocyclic aldehydes 1a-d or acetaldehyde 1e. The treatment of several rhodanine derivatives 3a-d and 3e with piperidine or morpholine in THF under reflux, afforded (Z)-5-(hetarylmethylidene)-2-(piperidin-1-yl)thiazol-4(5H)-ones and 2-morpholinothiazol-4(5H)-ones 5a-d, 6a-d, and (Z)-5-ethylidene-2-morpholinothiazol-4(5H)-one (5e), respectively, in good yields. Structures of all compounds were determined by IR, 1D and 2D NMR and mass spectrometry. Several of these compounds were screened by the U.S. National Cancer Institute (NCI) to assess their antitumor activity against 60 different human tumor cell lines. Compound 3c showed high activity against HOP-92 (Non-Small Cell Lung Cancer), which was the most sensitive cell line, with GI50 = 0.62 µM and LC50 > 100 µM from the in vitro assays. In vitro antifungal activity of these compounds was also determined against 10 fungal strains. Compound 3e showed activity against all fungal strains tested, but showed high activity against Saccharomyces cerevisiae (MIC 3.9 µg/mL).


Subject(s)
Antifungal Agents , Antineoplastic Agents , Heterocyclic Compounds, 2-Ring , Saccharomyces cerevisiae/growth & development , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/chemistry , Heterocyclic Compounds, 2-Ring/pharmacology , Humans , Magnetic Resonance Spectroscopy , Mass Spectrometry
7.
J Mol Graph Model ; 32: 19-31, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22030023

ABSTRACT

Selective modulation of liver X receptor beta (LXRß) has been recognized as an important approach to prevent or reverse the atherosclerotic process. In the present work, we have developed robust conformation-independent fragment-based quantitative structure-activity and structure-selectivity relationship models for a series of quinolines and cinnolines as potent modulators of the two LXR subtypes. The generated models were then used to predict the potency of an external test set and the predicted values were in good agreement with the experimental results, indicating the potential of the models for untested compounds. The final 2D molecular recognition patterns obtained were integrated to 3D structure-based molecular modeling studies to provide useful insights into the chemical and structural determinants for increased LXRß binding affinity and selectivity.


Subject(s)
Drug Design , Heterocyclic Compounds, 2-Ring/chemistry , Orphan Nuclear Receptors/chemistry , Peptide Fragments/chemistry , Quinolines/chemistry , Cholesterol/metabolism , Computer Simulation , Coronary Disease/drug therapy , Heterocyclic Compounds, 2-Ring/pharmacology , Humans , Ligands , Liver X Receptors , Models, Molecular , Molecular Conformation , Protein Conformation , Quantitative Structure-Activity Relationship , Quinolines/pharmacology , Substrate Specificity
8.
J Nat Prod ; 73(10): 1694-700, 2010 Oct 22.
Article in English | MEDLINE | ID: mdl-20923180

ABSTRACT

Two new five-membered-ring polyketide endoperoxides, epiplakinic acid F methyl ester (1) and epiplakinidioic acid (3), and a peroxide-lactone, plakortolide J (2), were isolated from the Puerto Rican sponge Plakortis halichondrioides, along with two previously reported cyclic peroxides, 4 and 5. The structures of the new metabolites were determined by spectroscopic and chemical analyses. The absolute stereostructures of 1, 2, and 5 were determined by degradation reactions followed by application of Kishi's method for the assignment of absolute configuration of alcohols. Biological screening of cycloperoxides 1-5 and semisynthetic analogues 7-12 for cytotoxic activity against various human tumor cell lines revealed that compounds 3, 4, and 11 are very active. Upon assaying for antimalarial and antitubercular activity, some of the compounds tested showed strong activity against the pathogenic microbes Plasmodium falciparum and Mycobacterium tuberculosis.


Subject(s)
Antimalarials/isolation & purification , Antimalarials/pharmacology , Antitubercular Agents/isolation & purification , Antitubercular Agents/pharmacology , Heterocyclic Compounds, 2-Ring/isolation & purification , Heterocyclic Compounds, 2-Ring/pharmacology , Peroxides/isolation & purification , Peroxides/pharmacology , Plakortis/chemistry , Animals , Antimalarials/chemistry , Antitubercular Agents/chemistry , Heterocyclic Compounds, 2-Ring/chemistry , Humans , Molecular Structure , Mycobacterium tuberculosis/drug effects , Peroxides/chemistry , Plasmodium falciparum/drug effects , Puerto Rico
9.
J Chem Inf Model ; 48(1): 213-9, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18163603

ABSTRACT

In the present study a systematic approach was used to model the anti-T. cruzi activity of a series of N-oxide containing heterocycles belonging to four chemical families with a wide structural diversity. The proposed mode of action implies the reduction of the N-oxide moiety; however, the biochemical mechanism underlying the anti-T. cruzi activity is still unkown. For structural representation two types of descriptors were analyzed: quantum chemical (AM1) global descriptors and properties coded by radial distribution function (RDF). Both types of descriptors point to the relevance of electronic properties. The local-RDF (LRDF) identified an electrophilic center at 4.1-4.9 A from the oxygen atom of the N-oxide moiety, although other properties are required to explain the biological activity. While the mode of action of N-oxide containing heterocycles is still unknown, the results obtained here strengthen the importance of the electrophilic character of the molecule and the possible participation of the heterocycle in a reduction process. The ability of these descriptors to distinguish among activity classes was assessed using Kohonen neural networks, and the best clustering descriptors were later used for model building. Different learning algorithms were used for model development, and stratified 10-fold cross-validation was used to evaluate the performance of each classifier. The best results were obtained using k-nearest neighbors (k-NN) and decision tree (J48) methods combined with global descriptors. Since tree-based methods are easily translated into classification rules, the J48 model is a useful tool in the de novo construction of new N-oxide containing heterocycle lead structures.


Subject(s)
Antiprotozoal Agents/chemistry , Antiprotozoal Agents/pharmacology , Computer Simulation , Heterocyclic Compounds, 2-Ring/chemistry , Heterocyclic Compounds, 2-Ring/pharmacology , Oxides/chemistry , Trypanosoma cruzi/drug effects , Algorithms , Animals , Drug Design , Models, Biological , Neural Networks, Computer , Principal Component Analysis , Quantitative Structure-Activity Relationship , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL